Close Menu

New Products

Oct 14, 2020

Paragon Genomics CleanPlex ARS-CoV-2-Related NGS Assays

Paragon Genomics has launched four new coronavirus-related CleanPlex next generation sequencing (NGS) assays. The new panels widen the capabilities of the firm's CleanPlex SARS-CoV-2 Research and Surveillance Panel, which allows researchers to sequence the SARS-CoV-2 genome and obtain accurate nucleic acid-level information on the virus for strain typing, mutation monitoring, and other epidemiological studies.

Paragon's CleanPlex ACE2 & TMPRSS2 Panel identifies genetic mutations in patients that are related to disease susceptibility and severity. The test targets genes affecting the binding affinity and expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine rotease 2 (TMPRSS2). The panel interrogates the entire coding region of ACE2 and TMPRSS2, along with more than 70 curated unique quantitative trait loci that regulate their expression. Paragon noted the panel uses CleanPlex technology's three-hour workflow to produce enriched NGS libraries for all major sequencing platforms.

Paragon's CleanPlex SARS-CoV-2 FLEX Research Panel anticipates increases in SARS-CoV-2 viral mutations and offers extra assurance that mutation detection and genome coverage remain optimal. The FLEX panel specifically focuses on variant analysis and tracking of mutations over time. The test also includes degenerate primers and human RNA primer controls for more confident negative sample calling, especially when viral copies are not present or are at extremely low counts, the firm said.

The company also launched its plated 384 Unique Dual-Indexed PCR Primers for Illumina sequencing of its CleanPlex SARS-CoV-2 NGS panels. The primers will allow additional multiplexing capability so that researchers can simultaneously run up to 3,072 CleanPlex sequencing samples on Illumina NovaSeq instruments.

In anticipation of the upcoming flu season, Paragon is also releasing an early-access edition of the CleanPlex Respiratory Research Panel, which combines assays for SARS-CoV-2, influenza A subtypes H1N1, H1N2, H3N2, and influenza B. The combination panel allows for simultaneous influenza detection with SARS-CoV-2 detection or whole-genome sequencing. The extra sensitivity and additional coverage of the multiplex PCR-based method also works for high-throughput sample pooling and screening strategies, the firm said. Paragon expects to expand the panel to include respiratory syncytial virus and possibly other respiratory viruses in the future.

Oct 13, 2020

Purigen Biosystems Ionic Cells to Pure DNA Low Input Kit

Purigen Biosystems has launched its Ionic Cells to Pure DNA Low Input kit for DNA extraction and purification prior to next-generation sequencing or qPCR.

The automated workflow takes one hour and provides consistent yields for as many as 10,00 cultured or sorted cells and as few as 10. According to Purigen, the kit delivers a higher proportion of DNA longer than 20 kb than column-based products. The kit includes six fluidic chips  for use on its benchtop Ionic Purification system and the necessary reagents to process 48 samples.

Oct 12, 2020

Exact Sciences Oncotype MAP Pan-Cancer Tissue Test

Exact Sciences has introduced the Oncotype MAP Pan-Cancer Tissue rapid, comprehensive tumor profiling panel test for patients with advanced, metastatic, refractory, or recurrent cancer. Oncotype MAP provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, including tumor mutations, copy number variants, fusions, tumor mutation burden, microsatellite instability, and protein expression, allowing physicians to understand a patient's tumor profile and effectively recommend targeted therapies or clinical trials, the company said.

The test, which Exact acquired as part of its merger deal with Paradigm Diagnostics in February, was previously called PCDx. 

Oncotype MAP has a turnaround time of three to five business days to guide timely treatment decisions, a sample requirement of as little as 3 mm of tissue or 2-3 slides, and accurate and comprehensive results based on next generation sequencing and immunohistochemistry. Exact also noted that patients who used a previous generation of the test had a 43 percent rate of progression-free survival compared to 5 percent for patients who did not utilize the test.

The Oncotype MAP test report is based on NCCN Compendium-based recommendations, along with potential evidence-based therapies and clinical trials. The report is currently tailored to support clinical decision-making by showing actionable biomarkers associated with more than 100 evidence-based therapies, more than 45 combination therapies, and more than 650 active clinical trial associations, Exact added.

Oct 12, 2020

Creative Biogene NGS Library Preparation Kits

Creative Biogene has launched new next-generation sequencing library preparation kits for DNA and RNA. The kits cover all steps of library construction, including fragmentation, amplification, adapter ligation, enrichment, and both dual- and single-index barcoding. Creative Biogene's kits are for research use only and can be adapted for automated lab protocols.

Oct 09, 2020

Bio-Rad Laboratories Opus Real-Time PCR Systems and BR.io Software

Bio-Rad Laboratories has launched two new qPCR instruments, the CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems. The systems offer enhanced usability, with features designed for academic, commercial, and biopharma labs. The firm also announced early access to BR.io, a cloud-based software that enables users to design experiments, analyze data, and access their experiments remotely.

Oct 07, 2020

Swift Biosciences Swift 2S Sonic DNA Library Kit

Swift Biosciences has released the Swift S2 Sonic DNA Library kit for next-generation sequencing of sheared DNA. The sample preparation kit is available in two configurations, for PCR indexing and for PCR-free indexing by ligation. It is compatible with Swift's Normalase technology and requires two hours of sample handling time.

The kits can be used for targeted hybridization capture with panels from Swift, Integrated DNA Technologies, and Twist Bioscience. The Swift HiFi Polymerase Master Mix supplied in the kits is suitable for pre-hybridization PCR to produce yields of 500 ng or greater, from as low as 1 ng DNA input.

The 96 reaction Swift 2S Sonic DNA library kit has a list price of $2,150.

Oct 07, 2020

Meridian Bioscience Inhibitor-Resistant qPCR Chemistries

Meridian Bioscience launched two novel inhibitor-resistant qPCR chemistries for the detection of DNA and RNA molecules directly from liquid biopsy samples without needing nucleic acid extraction. The mixes can be used to develop cancer diagnostic tests and workflows requiring fast turnaround times while ensuring high specificity. 

The mixes can tolerate high levels of inhibitors in blood, allowing for improvements in limit of detection by adding more sample in the reaction, Meridian said. Studies have shown superior sensitivity compared to other mixes, even in samples with difficult conditions, such as 20 percent blood, the company added. 

Establishing molecular tests to detect circulating cancer biomarkers can be difficult due to sample variability and inhibitory properties of the specimen, issues Meridian says its two new mixes can help fix. 

Oct 06, 2020

Biocartis: SeptiCyte Rapid

Biocartis has launched its CE-marked SeptiCyte Rapid assay for its Idylla platform. The test distinguishes sepsis from non-infectious systemic inflammation in patients suspected with sepsis and provides results within an hour, the firm said. 

Oct 05, 2020

Pacific Biosciences Sequel IIe System, SMRT Link 10 Software

Pacific Biosciences has launched the Sequel IIe system. This updated version of the Sequel II single-molecule sequencing instrument is optimized to generate the firm's HiFi reads directly. The Sequel IIe eliminates the need for post-processing and can reduce secondary analysis time by up to 70 percent, with up to a 90 percent reduction in file transfer and data storage costs.

PacBio has also added new tools to its SMRT Link software to enable complete workflow integration on Amazon Web Services cloud computing and a new genome assembly analysis application for generating reference-quality de novo assemblies from HiFi reads.

Oct 02, 2020

New England Biolabs Luna Probe One-Step RT-qPCR 4X Mix with UDG

New England Biolabs has launched the Luna Probe One-Step RT-qPCR 4X Mix with UDG. The master mix is optimized for the sensitive detection of target RNA sequences for probe-based applications, and allows for increased throughput by multiplexing up to five targets. 

The product features also include 4X concentration for increased amounts of sample input, addition of UDG and dUTP to reduce the risk of carryover contamination, Luna WarmStart RT paired with Hot Start Taq for reactions at room temperature, and a visible, non-interfering blue tracking dye for ease of use.

Oct 01, 2020

Imec elPrep5

Imec has introduced elPrep5, the latest iteration of its DNA analytics platform. The new release of elPrep adds variant calling and takes advantage of parallel computing to perform a complete analysis in a single pass. The Belgian nanoelectronics and digital technology company claimed that elPrep5 can process a whole-genome sequence eight to 16 times faster than the Broad Institute's benchmark Genome Analysis Toolkit (GATK).

Oct 01, 2020

Discovery Life Sciences SpecimenSeq

Discovery Life Sciences has launched SpecimenSeq, a collection of high-quality, fully consented biospecimens to help researchers identify, develop, and validate new biomarker signatures for precision medicine applications.

SpecimenSeq is composed of matched biospecimen sets including FFPE, double-spun plasma, and buffy coat formats from treatment-naive cancer patients. The biospecimens are fully annotated with clinical data and the FFPE biospecimens specifically include clinically relevant genomic variants from 64 genes. Genomic data for SpecimenSeq are produced using the custom HAD QGEN MultiModal Panel-based DNA and RNA analysis service available exclusively through Discovery's sequencing and bioinformatics laboratory, HudsonAlpha Discovery. This panel service uses Qiagen's QIAseq MultiModal targeted DNA and RNA sequencing chemistry and analysis platform that is also available as a standalone service through HudsonAlpha Discovery with variant allele frequency detection at less than 5 percent.

Oct 01, 2020

LGC Seracare Seraseq Oncology Reference Controls

LGC Seracare has added four new products to its somatic cancer reference control portfolio. The Seraseq MSI Reference Panel Mix AF5% and AF20% are the company's first microsatellite instability reference materials that target the lengths of the regions commonly referred to as BAT-25, BAT-26, NR-21, NR-24, and MONO-27. These markers are blended at two different allele frequency levels (5 percent and 20 percent) to support MSI assay limit of detection determinations and accurate analysis of MSI status of patient samples.

The Seraseq NTRK Fusion RNA Mix is a 15-plex RNA mix of NTRK fusion genes that are important in next-generation sequencing assay evaluation of cancer patients harboring NTRK fusions for therapeutic intervention. This new product complements LGC Seracare's existing 15-plex FFPE NTRK reference material.

The Seraseq Compromised FFPE WT (DNA/RNA) RM is a more "patient-like (compromised)" negative sample control in FFPE format. A single FFPE section offers both RNA and DNA for targeted NGS assay validation and/or routine use in clinical testing. This product is complementary to the recently released Seraseq TNA WT (DNA/RNA) as well as mutation-positive Seraseq DNA and RNA reference materials, the company said.

All products are available in purified and FFPE formats, the company said.

Oct 01, 2020

OriCiro Genomics Cell-Free Cloning System

OriCiro Genomics has launched its Cell-Free Cloning System, the world's first technology enabling cell-free amplification of large circular DNA, eliminating the reliance on Escherichia coli cloning. Thes ystem comprises the OriCiro Assembly Kit and OriCiro Amp Kit. A simple two-step in vitro process enables cell-free assembly and amplification of circular DNA molecules without the need for E. coli transformation and culture, the company said.

Oct 01, 2020

PCR Biosystems NGSBIO Library Quant Kit

PCR Biosystems has launched the NGSBio Library Quant kit for Illumina next-generation sequencing platforms.

The kit enables accurate and sensitive quantification of DNA libraries and generates more clustering data per run than previous solutions. The kit contains five DNA standards, primers specific to the P5 and P7 Illumina adapter sequences, a library dilution buffer, and qPCRBio SyGreen Mix or qPCRBio SyGreen Blue mix. The blue qPCR mix contains a non-reactive dye to improve reaction mix visibility.

Accompanying the kit is a free online calculator to help researchers analyze results with the kit.

Sep 29, 2020

Igenomix Embrace

Igenomix has launched Embrace, a non-invasive test for prioritizing embryo transfer. Embrace scores embryos according to their probability of being healthy and viable based on chromosomal information.  Rather than removing cells from a developing embryo through biopsy, Embrace enables scientists at Igenomix to use next-generation sequencing to test the drop of the culture medium in which a six-day-old embryo, or blastocyst, has developed to count the chromosome number of the embryonic cell-free DNA. A score is then given to determine the probability of the embryo being healthy and viable, the company said. According to the company the test will enable embryonic chromosome analysis to be accessible to a larger number of in vitro fertilization centers and patients, as it simplifies the process and increases chances of IVF success. Igenomix said that it is offering Embrace to the 400 US fertility centers it currently works with.

Sep 25, 2020

Seven Bridges RHEO Visual Interface for Multi-Omic Analysis

Seven Bridges has introduced the RHEO Visual Interface workflow automation tool for multi-omic analysis. RHEO can completely auto-generate a visual interface from a developer's automation script, and complements the existing command line interface for automations releases by the company last year. The interface minimizes the time and effort required to set up and run data-analysis workflows for biologists, particularly those who work with experimental data but do not have extensive training in workflow automation, Seven Bridges said. Additional benefits include installation-free use, automatic authentication, instant collaboration, comprehensive audit logs, versioning and 100 percent reproducibility, all within a secure and compliant cloud environment, the company added.

Sep 24, 2020

LabCorp Resolution ctDx Lung Assay

LabCorp has launched the Resolution ctDx Lung assay for patients with non-small cell lung cancer (NSCLC). The test will be run by Resolution Biosciences and detects actionable mutations associated with the disease in a standard blood sample. The firm said the test can provide valuable information to help select the most effective targeted treatments for individual patients. In addition, LabCorp noted that the test is covered by Medicare. 

Sep 23, 2020

CRISPR QC and Cardea Bio CRISPR-BIND

CRISPR quality control testing firm CRISPR QC and Cardea Bio have launched CRISPR-BIND, a rapid and highly sensitive tool to characterize guide RNA and CRISPR-Cas interactions. CRISPR-BIND is the first product in a suite of quality control capabilities, and is built on Cardea's biology-gated transistors and an automated, high-throughput liquid handler to generate highly sensitive electronic signals that allow for rapid assessments of gRNA-Cas interactions directly at the bench. This includes, but is not limited to, monitoring the interactions and stability of a variety of modified gRNAs with engineered Cas enzymes.

CRISPR QC will commercialize CRISPR-BIND in the US in partnership with COBO Technologies, which will offer the product in Europe, the firms said. CRISPR QC is Cardea's first commercial partner and CRISPR-BIND is the first of a series of CRISPR QC applications that they expect to come out of the partnership.

Sep 23, 2020

Congenica COVID-19 Module

Congenica has added a COVID-19 module to its genomic analysis platform. The company said that the new add-on will support research into relationships between a patient's genome and COVID-19 infection risk, severity, and clinical outcomes. The module also helps researchers prioritize variants in curated genes based on Human Phenotype Ontology terms that suggest COVID-19 symptoms.  

Sep 23, 2020

Exagen Avise Vasculitis AAV

Exagen launched the Avise Vasculitis AAV test panel of individual analytes to assess and monitor anti-neutrophil cytoplasmic antibody-associated vasculitis. ANCA-associated vasculitis is characterized by vascular inflammation and damage, and early symptoms of the disease vary widely. Exagen's test is intended for use in patients suspected of small vessel diseases, such as granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. 

Sep 22, 2020

Bio-Techne RNA-Protein Co-Detection Assays

Bio-Techne has expanded its Advanced Cell Diagnostics-branded RNAscope technology with the release of RNA-Protein Co-Detection Assays. RNAscope technology is an advanced in situ hybridization assay that enables visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues. The codetection assays allow researchers to simultaneously examine gene expression specific to cell types and identify cellular sources of secreted proteins. The new workflow enables a wider range of IHC-validated antibodies to be combined with RNA ISH.

Sep 18, 2020

Bio-Rad Laboratories StarBright Violet 515 Dye for Flow Cytometry

Bio-Rad Laboratories has launched the StarBright Violet 515 (SBV515) dye, the first of a new range of fluorescent nanoparticles for flow cytometry. SBV515 has an excitation maximum at 401 nanometers and emission maximum of 516 nanometers, offering improved brightness to better resolve rare and low antigen density populations. It has a narrow emission profile to reduce spillover into neighboring filters and minimize excitation by other lasers, making it suitable for inclusion in multicolor panels. The dye is not susceptible to photobleaching, delivers high lot-to-lot reproducibility, and is stable at 4° C with no loss of signal, Bio-Rad said.

Sep 18, 2020

Akoya Biosciences Proxima Spatial Biology Platform

Akoya Biosciences this week launched the Proxima Spatial Biology Platform to integrate rapid image acquisition and secure data sharing in the cloud. The new software is designed to allow users to visualize and analyze whole-slide, multiplexed immunofluorescence images generated by Akoya's Phenoptics platform, and will soon be expanded to visualize and analyze ultra-high-plex images generated by Akoya's CODEX platform, enabling an integrated, flexible, and scalable solution from discovery to translational and clinical research, the company said.

Sep 18, 2020

RenalytixAI: KidneyIntelX

RenalytixAI has announced the commercial launch of its KidneyIntelX clinical testing platform, which provides risk assessment of progressive decline in kidney function or kidney failure in patients with early-stage diabetic kidney disease. KidneyIntelX applies machine-learning algorithms to assess predictive blood-based biomarkers and electronic health record data to identify progressive kidney disease in at-risk patients. 

The firm submitted a 510(k) application to the US Food and Drug Administration for the assay last month. 

Pages

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.